(CN) - A federal judge refused to toss Procaps' antitrust claims against collaborator Patheon, saying the drugmaker's alleged injuries are not self-inflicted simply because it "could have ducked the ...

Patheon, an Amsterdam-based contract drug developer, said in a regulatory filing it plans to raise $625 million in a public offering that analysts forecast would give the company a market value of ...

Patheon uses many innovative technologies including single-use disposables, liquid-filled hard capsules and a variety of modified release technologies. Patheon's comprehensive range of fully ...

Patheon is awaiting finalization of a $7.2 billion deal that will make it a part of Thermo Fisher Scientific, but in the meantime the CDMO is moving forward with expansion plans at sites that stretch ...

(Reuters) - Thermo Fisher Scientific Inc said on Monday it would buy Patheon NV, a Dutch manufacturer of drugs for clinical trials, for $5.2 billion as it seeks to complement its offerings in ...

IPO headwinds? What IPO headwinds? In a market that has blown away many biotechs seeking to go public, the pharma services industry continues to buck a negative trend as Patheon sets its terms for an ...

May 15 (Reuters) - Thermo Fisher Scientific Inc, the world's largest maker of scientific instruments, said on Monday it would buy contract manufacturing company Patheon NV for about $5.2 billion in ...

TORONTO and HIGH POINT, NC. – October 29, 2012 – Patheon Inc. (TSX: PTI), a leading provider of contract development and manufacturing services to the global pharmaceutical industry, today announced ...

Thermo Fisher Scientific plans to acquire Patheon for approximately $7.2 billion cash, the companies said today, in a deal that expands the buyer into the contract development and manufacturing ...

In response to the company accepting a buyout offer, shares of Patheon N.V. (NYSE: PTHN) , a provider of development and manufacturing services for the pharmaceutical industry, jumped 33% as of 10:45 ...

Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. Thermo Fisher Scientific on Monday unveiled a $7.2bn deal to buy Patheon, a company that helps biotech and ...

Contract drug maker Patheon Inc., still smarting from an insider trading probe, is buying rival MOVA Pharmaceuticals Corp. of Puerto Rico for as much as $316-million (U.S.) in a deal that will make ...